Back pain is the number one cause of disability in the world and more money is spent treating it than all forms of cancer combined. DiscGenics is developing a treatment that doesn’t just relieve the pain, but has the potential to cure its underlying cause. DiscGenics is a clinical stage biopharma company and it has an allogeneic cell therapy made with proprietary cells to treat adult lumbar disc degeneration. In a Phase I/II clinical trial, patients demonstrated a rapid, durable, and statistically significant reduction in pain with increased function and quality of life in just 12 weeks that was sustained for two years thanks to the treatment’s ability to regenerate disc cells. DiscGenics has completed the construction of its own GMP manufacturing facility and hopes to gain conditional marketing approval in Japan in 2023 with the U.S. following on. The company has a broad patent portfolio that includes method of use, identity, manufacture, and several trade secrets surrounding its GMP certified manufacturing facility in Salt Lake City, Utah.